Home > Gastroenterology > IV ferric carboxymaltose tops IV iron sucrose for iron-deficiency anemia in IBD

IV ferric carboxymaltose tops IV iron sucrose for iron-deficiency anemia in IBD

Journal
Cochrane Database of Systematic Reviews
Reuters Health - 01/02/2021 - For iron-deficiency anemia (IDA) in patients with inflammatory bowel disease (IDA), intravenous ferric carboxymaltose is probably a better bet than IV iron sucrose, according to a Cochrane review of therapies to treat IDA in patients with Crohn's disease (CD) and ulcerative colitis (UC). The reviewers note that IBD affects roughly seven million people around the world and is often accompanied by IDA. The different routes of iron administration, doses and preparations have varying advantages and disadvantages, yet "no consensus has been reached amongst physicians as to which treatment path is most beneficial," they say. Using data available through November 2019, Dr. Morris Gordon of the University of Central Lancashire, in Preston, U.K., and colleagues evaluated the efficacy and safety of the various interventions for treatment of IDA in patients with IBD. Eleven studies, with a total of 1,670 participants, met their inclusion cr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on